Orchestra BioMed Holdings, Inc. (OBIO)
Automate Your Wheel Strategy on OBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including OBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OBIO
- Rev/Share 0.0755
- Book/Share 0.4409
- PB 7.3037
- Debt/Equity 0.1249
- CurrentRatio 3.351
- ROIC -1.5582
- MktCap 123366250.0
- FreeCF/Share -1.4242
- PFCF -2.2656
- PE -1.8565
- Debt/Assets 0.0357
- DivYield 0
- ROE -1.8926
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OBIO | BTIG Research | -- | Buy | -- | $12 | March 20, 2025 |
| Initiation | OBIO | Barclays | -- | Overweight | -- | $16 | Jan. 2, 2025 |
| Initiation | OBIO | H.C. Wainwright | -- | Buy | -- | $14 | Aug. 22, 2024 |
News
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of key clinical insights into the role of AVIM therapy for the treatment of high-risk hypertension at the Congenital, Structural, and Valvular Heart Disease Interventions (“CSI”) 2025 Meeting. The data highlight AVIM therapy's unique potential to address hypertensive heart disease, a significant and under-recognized cardiovascular syndrome that affects a growing segment of the aging hypertension population.
Read More
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced continued expansion of its global intellectual property (IP) estate supporting its proprietary AVIM therapy pipeline (formerly known as Cardiac Neuromodulation Therapy or “CNT”). Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its …
Read More
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.
Read More
Orchestra BioMed to Present at Upcoming Investor Conferences
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.
Read More
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio.
Read More
About Orchestra BioMed Holdings, Inc. (OBIO)
- IPO Date 2020-08-04
- Website https://orchestrabiomed.com
- Industry Biotechnology
- CEO David P. Hochman
- Employees 70